Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c

Fang, Zenghui; Li, Tong; Chen, Wanzhou; Wu, Du; Qin, Yaqian; Liu, Min; Wu, Guang; He, Licai; Li, Hongzhi; Gu, Haihua

doi:10.1016/j.yexcr.2019.06.007

Cited by 24 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor growth was monitored on day 14 (just before anti-tumor treatment) and 28 (after anti-tumor treatment for 14 days) using Lumina Series III IVIS imaging system (PerkinElmer, MA, USA) as described ( 35 ). Briefly, on the day of IVIS imaging, mice were first anesthetized with isoflurane (RWD Life Science, Shenzhen, China) and then injected with 150 mg/kg luciferase solution (PerkinElmer) intraperitoneally.…”

Section: Methodsmentioning

confidence: 99%

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice

Yang

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Chimeric Antigen Receptor (CAR)-T cells have great efficacy against CD19 + leukemia but little success for solid tumors. This study explored the effectiveness of third generation anti-HER2 CAR-T cells alone or in combination with anti-PD1 antibody on breast tumor cells expressing HER2 in vitro and in immune competent mouse model. The PDL1-positive mouse mammary tumor cell line 4T1 engineered to express luciferase and human HER2 was used as the target cell line (4T1-Luc-HER2). Anti-HER2 CAR-T cells were generated by transducing mouse spleen T cells with recombinant lentiviruses. ELISA analysis showed that IL-2 and IFN-γ secretion was increased in CAR-T cells co-cultured with the target cells, and the secretion of these two cytokines was increased further with the addition of anti-PD1 antibody. Lactate dehydrogenase assay revealed that CAR-T cells displayed a potent cytotoxicity against the target cells, and the addition of anti-PD1 antibody further enhanced the cytotoxicity. At the effector: target ratio of 16:1, cytotoxicity was 39.8% with CAR-T cells alone, and increased to 49.5% with the addition of anti-PD1 antibody. In immune competent syngeneic mouse model, CAR-T cells were found to be present in tumor stroma, inhibited tumor growth and increased tumor apoptosis significantly. Addition of anti-PD1 antibody further enhanced these anti-tumor activities. Twenty-one days after treatment, tumor weight was reduced by 50.0% and 73.3% in CAR-T group and CAR-T plus anti-PD1 group compared with blank T group. Our results indicate that anti-PD1 antibody can greatly increase the efficacy of anti-HER2 CAR-T against HER2-positive solid tumors.

show abstract

Section: Methodsmentioning

confidence: 99%

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice

Yang

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…MCF10A cell line was a gift from Dr. Joan Brugge (Harvard Medical School). 293T17 cell line was as described 26 . BT474 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Lonsera), 100 units/mL penicillin and 100 μg/mL streptomycin (Beyotime Institute of Biotechnology).…”

Section: Methodsmentioning

confidence: 99%

“…For the production of lentivirus, 293T17 cells were cotransfected with PLKO.1 plasmid together with 2 packaging plasmids, pCMV‐VSV‐G and delta 8.9 as described 27 . For the production of retrovirus, 293T17 cells were cotransfected with retroviral plasmid together with 2 packaging plasmids, pCMV‐VSV‐G and gag/pol as described 26 . Harvested virus supernatants were filtered through a 0.45 μm low protein‐binding sterile filter.…”

Section: Methodsmentioning

confidence: 99%

24‐Dehydrocholesterol reductase promotes the growth of breast cancer stem‐like cells through the Hedgehog pathway

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, CD44 also can be regulated by various molecules, signaling and some drugs. Some micro-RNAs have been found to negatively modulate CD44 expression, such as microRNA-150 [39], microRNA-200c [88], microRNA-34a [33], microRNA-330-5p [89], micro-RNA-145 [90], microRNA-3129 [91], microRNA-143 [92], microRNA-328 [93], and microRNA-373 [94]. CD44 has been reported to be a novel downstream target of microRNA-150 in nasopharyngeal carcinoma [39].…”

Section: Molecules and Pathways That Cd44 Regulatesmentioning

confidence: 99%

CD44 as a tumor biomarker and therapeutic target

et al. 2020

View full text Add to dashboard Cite

CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem cells, and promotes epithelial-mesenchymal transition. CD44 is involved in the regulation of diverse vital signaling pathways that modulate cancer proliferation, invasion, metastasis and therapy-resistance, and it is also modulated by a variety of molecules in cancer cells. In addition, CD44 can serve as an adverse prognostic marker among cancer population. The pleiotropic roles of CD44 in carcinoma potentially offering new molecular target for therapeutic intervention. Preclinical and clinical trials for evaluating the pharmacokinetics, efficacy and drug-related toxicity of CD44 monoclonal antibody have been carried out among tumors with CD44 expression. In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in carcinogenesis and cancer progression as well as the potential CD44-targeting therapy for cancer management.

show abstract

Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c

Cited by 24 publications

References 45 publications

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice

24‐Dehydrocholesterol reductase promotes the growth of breast cancer stem‐like cells through the Hedgehog pathway

CD44 as a tumor biomarker and therapeutic target

Contact Info

Product

Resources

About